Royal Prince Alfred Hospital

Running trials

• Not yet recruiting

  Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR

  NCT07696182· Abbott Medical Devices· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

  NCT07830732· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

  NCT07717411· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy

  NCT07576335· Phase 2· Surgical Outcomes Research Centre (SOuRCe)· Source

• Recruiting

  A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

  NCT07754461· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

  NCT07662122· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

  NCT07416604· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Specific and Novel Approaches to Care of Inflammatory Bowel Disease During Pregnancy: the PREGO Study

  NCT07916727· Austin Health· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  RECOMMEND Platform Trial

  NCT06526533· Phase 3· Australian and New Zealand Intensive Care Research Centre· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Not yet recruiting

  Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)

  NCT07292519· Phase 2· South West Sydney Local Health District· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Not yet recruiting

  A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

  NCT07266324· Phase 2· Bright Minds Biosciences Pty Ltd· Source

• Recruiting

  A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  NCT06793397· Phase 3· Cybin IRL Limited· Source

• Not yet recruiting

  Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)

  NCT07247370· Phase 1/2· South West Sydney Local Health District· Source

• Active, not recruiting

  A Pivotal Study to Evaluate the Efficacy and Safety of a Totally Implantable Cochlear Implant (TICI) System in Adults

  NCT07139327· Cochlear· Source

• Active, not recruiting

  A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07170150· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

  NCT07149857· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  NCT07175038· Phase 2· AllRock Bio, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  CPAP and Glucose Metabolism in Non-Diabetic OSA Subjects

  NCT05335083· Woolcock Institute of Medical Research· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

  NCT06925750· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

  NCT06855329· University of Massachusetts, Worcester· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

  NCT06671496· Phase 3· Takeda· Source

• Recruiting

  The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

  NCT06763055· Phase 3· The George Institute· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT06291220· Phase 1· AbbVie· Source

• Recruiting

  A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

  NCT06585774· Phase 3· Incyte Corporation· Source

• Recruiting

  Safety of Discontinuing NSBBs in Cirrhotic Patients With Managed Primary Aetiological Factors

  NCT06549673· Chinese University of Hong Kong· Source

• Recruiting

  A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT06669247· Phase 1/2· Regeneron Pharmaceuticals· Source

• Enrolling by invitation

  Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

  NCT06723106· Phase 1· Chugai Pharmaceutical· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Active, not recruiting

  A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

  NCT06447168· Ipsen· Source

• Recruiting

  ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

  NCT06320431· Phase 3· University of Calgary· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

Showing 50 of 137.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis7 recruiting
• Haemophilia6 recruiting
• Multiple myeloma5 recruiting
• Stroke5 recruiting
• High blood pressure4 recruiting
• Alzheimer disease3 recruiting
• Crohn's disease3 recruiting
• Depression3 recruiting
• Type 2 diabetes3 recruiting
• Ulcerative colitis3 recruiting
• Acute myeloid leukaemia2 recruiting
• Childhood cancers2 recruiting
• Coronary artery disease2 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Epilepsy2 recruiting
• Immune thrombocytopenia (ITP)2 recruiting
• Liver and biliary tract cancer2 recruiting
• Liver cirrhosis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Obesity2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Heart failure1 recruiting
• Melanoma1 recruiting
• Obstructive sleep apnoea1 recruiting
• Osteoporosis1 recruiting
• Prostate cancer1 recruiting
• Sickle cell disease1 recruiting
• Thalassaemia1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

  NCT07108153· Phase 2· Sionna Therapeutics Inc.· Source

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

  NCT06424262· Cochlear· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS

  NCT06272981· Biosense Webster, Inc.· Source

• Terminated

  Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

  NCT05942911· Phase 2· Incannex Healthcare Ltd· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Indirect Calorimetry Guided Energy Provision in Critically Ill Patients With Obesity

  NCT06053216· Australian and New Zealand Intensive Care Research Centre· Source

• Completed

  SBD121, a Synbiotic Medical Food for RA Management

  NCT06005220· Solarea Bio, Inc· Source

• Completed

  BPL-003 Efficacy and Safety in Treatment Resistant Depression

  NCT05870540· Phase 2· Beckley Psytech Limited· Source

• Completed

  IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

  NCT05989711· Phase 2· Altimmune, Inc.· Source

• Completed

  A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

  NCT05470140· Phase 1· Allotera Therapeutics· Source

• Completed

  To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

  NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

  NCT05580692· BioMarin Pharmaceutical· Source

• Recruiting

  Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

  NCT05518578· Phase 2· Supernus Pharmaceuticals, Inc.· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· ApcinteX Ltd· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

  NCT05129722· Phase 4· The George Institute· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· United Therapeutics· Source

• Completed

  Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries

  NCT05556681· C. R. Bard· Source

• Completed

  A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

  NCT05014672· Phase 2· Calliditas Therapeutics Suisse SA· Source

• Completed

  An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

  NCT05223920· Phase 2· Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· University of Calgary· Source

• Completed

  Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

  NCT03734640· Craig Anderson· Source

• Completed

  A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

  NCT04763408· Eisai Inc.· Source

• Completed

  An Implementation Trial to Improve Access to Pulmonary Rehabilitation in People With COPD

  NCT04217330· Monash University· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

  NCT04323098· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

  NCT04535544· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source

• Terminated

  A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

  NCT04244656· Phase 1· CRISPR Therapeutics AG· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

  NCT03713593· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Pfizer· Source

• Completed

  Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

  NCT03370913· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

  NCT02699645· Phase 3· The George Institute· Source

• Terminated

  Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

  NCT03307980· Phase 2· Pfizer· Source

• Completed

  Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma

  NCT02166788· Phase 3· Melanoma and Skin Cancer Trials Limited· Source

• Completed

  Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

  NCT01842568· Population Health Research Institute· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· AbbVie· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Melanoma81 works · 3 trials
• Multiple myeloma30 works · 18 trials
• Congenital heart disease25 works · 0 trials
• Systemic sclerosis (scleroderma)24 works · 3 trials
• Pulmonary arterial hypertension11 works · 9 trials
• Idiopathic pulmonary fibrosis11 works · 16 trials
• Hypertrophic cardiomyopathy10 works · 1 trial
• Narcolepsy9 works · 0 trials
• Lewy body dementia6 works · 0 trials
• Haemophilia6 works · 14 trials
• Mesothelioma5 works · 0 trials
• Familial hypercholesterolaemia4 works · 1 trial